Drugs / TIFALIBEP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03502954 | Feb 2018 → Feb 2020 | — | Affibody | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIFALIBEP | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068597 ↗ |
| Known as | ABY-039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03502954 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068597 ↗ |
| Route | Intravenous | “ABY-039 IV” NCT03502954 ↗ |